Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | CD109 |
| Gene Name: | CD109 |
| Protein Full Name: | CD109 antigen |
| Alias: | 150 KDa TGF-beta-1-binding; 150 KDa TGF-beta-1-binding protein; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 7; CD109 molecule; CPAMD7; DKFZp762L1111; FLJ38569; FLJ41966; P180; Platelet-specific Gov; Platelet-specific Gov antigen; R150; RP11-525G3.1 |
| Mass (Da): | 161671 |
| Number AA: | 1445 |
| UniProt ID: | Q6YHK3 |
| Locus ID: | 135228 |
| COSMIC ID: | CD109 |
| Gene location on chromosome: | 6q13 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | GAIN |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19690 |
| Percent of cancer specimens with mutations: | 1.16 |
| Normal role description: | CD109 is a GPI-linked cell surface antigen expressed by CD34+ acute myeloid leukemia cell lines, T-cell lines, activated T lymphoblasts, endothelial cells, and activated platelets. It funtions to negatively regulate signalling of transforming growth factor beta (TGF-beta) -- a tumour suppressor. Mutations in this gene have been found in colon and ovarian tumors. |